HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40
HC Wainwright & Co. analyst Joseph Pantginis assumes Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $40.
Share
Why It Matters
An expert analyst thinks Odyssey Therapeutics is worth buying now. They believe the stock could reach $40 in the future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.